From Medscape Dermatology

International Society of Atopic Dermatitis (ISAD) 2021 Annual Meeting

April 19 - 20, 2021; Seoul, South Korea; Hybrid

April 19 - 20, 2021 Seoul, South Korea; Hybrid

Itch Response Faster With Abrocitinib Compared to Dupilumab An experimental oral Janus kinase 1 (JAK1) inhibitor, abrocitinib, showed greater itch reduction after 2 weeks of treatment than dupilumab in patients with moderate to severe atopic dermatitis, in a multicenter, randomized trial.
Medscape Medical News, Mar 25, 2021
Bacteriotherapy Passes Early Test in Atopic Dermatitis Study And perhaps most exciting," Gallo added, is the finding that the subset of patients with AD who were most responsive to the ShA9 compound...showed improvement in...scores used to assess inflammation.
Medscape Medical News, Mar 11, 2021
What Drives Treatment Satisfaction Among Adults With AD? AD management is complex. It includes patient education about trigger avoidance, over-the-counter and prescription topical therapies, as well as systemic therapies.
Medscape Medical News, Mar 08, 2021

Medscape Dermatology© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Previous Coverage

Related Resources